Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Rosenbaum

Infectious Disease Riverhead, NY Medical Doctor

NPI 1437261385 CMS profile 247244

887 Old Country Rd, Suite A, Riverhead, NY 11901

Open in the dashboard

General payments

$3,614

170 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Rosenbaum of Riverhead, NY is reported in the CMS Open Payments database as having received $3,614 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $288 14
2024 General $588 29
2023 General $645 28
2022 General $240 16
2021 General $676 31
2020 General $261 19
2019 General $916 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Rosenbaum
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Gary Rosenbaum were reported at $288. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Gary Rosenbaum Infectious Disease median Middle half National median
2019 $916 $190 $60–$862 $163
2020 $261 $124 $32–$606 $114
2021 $676 $148 $38–$905 $132
2022 $240 $166 $50–$834 $149
2023 $645 $171 $57–$787 $160
2024 $588 $176 $52–$752 $164
2025 $288 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $1,094 71 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $513 23 payments
  3. Romark Laboratories, LC $346 4 payments
  4. Janssen Biotech, Inc. $262 13 payments
  5. AbbVie, Inc. $175 11 payments
  6. RedHill Biopharma Inc. $146 7 payments
  7. Janssen Products, LP $131 2 payments
  8. Phathom Pharmaceuticals, Inc. $127 6 payments
  9. COMSORT, Inc $100 1 payment
  10. Daiichi Sankyo Inc. $74 4 payments
  11. Other $645 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,280 160 payments
  2. Education $234 9 payments
  3. Consulting Fee $100 1 payment
Products named General payments · program years 2019–2025
  1. ZERBAXA $816 53 payments
  2. DIFICID $614 41 payments
  3. XIFAXAN $513 23 payments
  4. RECARBRIO $388 28 payments
  5. ALINIA Gastroenterology $346 4 payments
  6. ALINIA Gastroenterology $346 4 payments
  7. ALINIA Gastroenterology $346 4 payments
  8. SYMTUZA $310 11 payments
  9. ZINPLAVA $279 21 payments
  10. SIVEXTRO $181 6 payments
  11. Other $1,810 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

266

Median for Infectious Disease: 268

Drug cost

$177,140

Median for Infectious Disease: $217,595

Branded share of claims

48.5%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 26 $98,186
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 12 $54,465
Ertapenem Ertapenem Sodium Brand 35 $16,355
Doxycycline Monohydrate Generic 33 $1,865
Ceftriaxone Ceftriaxone Sodium Brand 11 $1,759
Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam Brand 22 $1,353
Cefadroxil Generic 29 $682
Cefdinir Generic 11 $676
Linezolid Generic 12 $591
Amoxicillin Generic 16 $479

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$99,634

Medicare's payments for the services billed

Medicare patients

353

Average age 76

Services billed

1,217

168 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 56%
Diabetes 48%
Heart failure 43%
Chronic kidney disease 42%
Atrial fibrillation 41%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $158
$158 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $127
$127 — —
DIFICID
  • Merck Sharp & Dohme Corporation $71
$71 — —
ZERBAXA
  • Merck Sharp & Dohme Corporation $57
$57 — —
MAVYRET
  • AbbVie, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record